As many as 4 million people are suffering from brain fog, headaches, chest pain, and other long COVID symptoms. Paxlovid could help prevent them.
from the Veterans Health Administration is offering some hope for cutting the risk of developing the debilitating condition., which is intended to treat and relieve the symptoms of COVID-19, may also reduce the risk of developing long COVID following the initial infection by 26 percent. The research is a preprint that was posted online over the weekend, so it still has to undergo peer review.
The patients in the study had all tested positive for the coronavirus between March 1 and June 30 of 2022 when the contagiouswere the dominant strains of COVID. The study also finds that the benefits of taking Paxlovid applied to patients who were unvaccinated, vaccinated, and had repeat COVID-19 infections. All groups has a similar reduction of developing long COVID with the antiviral drug.
For those who are medically eligible to take Paxlovid , it reduces the risk of hospitalization or death. It works by“We know that one of the key factors that predict long COVID is detectable virus in the bloodstream at the time of infection,” Peter Chin-Hong, an infectious disease physician at the University of California, San Francisco,
. “So it stands to reason that interventions that prevent the virus from making more copies of itself would therefore lead to a lower risk of long COVID.”The authors point to the study as another motivation for patients to take Paxlovid as soon as they can after getting sick. Some have become weary of using the anti-viral due to the
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New VA study finds Paxlovid may cut the risk of long COVIDFor those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
Read more »
Paxlovid reduces risk of long Covid, Veterans Affairs study finds | CNNPaxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a new study by researchers at the US Department of Veterans Affairs.
Read more »
New VA study finds Paxlovid may cut the risk of long COVIDFor those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
Read more »
Paxlovid reduces long-COVID risk, VA study findsPfizer's antiviral pill Paxlovid can reduce the risk of long COVID symptoms like organ damage, per a pre-print study released by the Dept. of Veterans Affairs.
Read more »